1
|
Toft PB, Yashiro H, Erion DM, Gillum MP, Bäckhed F, Arora T. Microbial dietary protein metabolism regulates GLP-1 mediated intestinal transit. FASEB J 2023; 37:e23201. [PMID: 37732618 DOI: 10.1096/fj.202300982r] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 08/21/2023] [Accepted: 09/05/2023] [Indexed: 09/22/2023]
Abstract
Depletion of gut microbiota is associated with inefficient energy extraction and reduced production of short-chain fatty acids from dietary fibers, which regulates colonic proglucagon (Gcg) expression and small intestinal transit in mice. However, the mechanism by which the gut microbiota influences dietary protein metabolism and its corresponding effect on the host physiology is poorly understood. Enteropeptidase inhibitors block host protein digestion and reduce body weight gain in diet-induced obese rats and mice, and therefore they constitute a new class of drugs for targeting metabolic diseases. Enteroendocrine cells (EECs) are dispersed throughout the gut and possess the ability to sense dietary proteins and protein-derived metabolites. Despite this, it remains unclear if enteropeptidase inhibition affects EECs function. In this study, we fed conventional and antibiotic treated mice a western style diet (WSD) supplemented with an enteropeptidase inhibitor (WSD-ETPi), analyzed the expression of gut hormones along the length of the intestine, and measured small intestinal transit under different conditions. The ETPi-supplemented diet promoted higher Gcg expression in the colon and increased circulating Glucagon like peptide-1 (GLP-1) levels, but only in the microbiota-depleted mice. The increase in GLP-1 levels resulted in slower small intestinal transit, which was subsequently reversed by administration of GLP-1 receptor antagonist. Interestingly, small intestinal transit was normalized when an amino acid-derived microbial metabolite, p-cresol, was supplemented along with WSD-ETPi diet, primarily attributed to the reduction of colonic Gcg expression. Collectively, our data suggest that microbial dietary protein metabolism plays an important role in host physiology by regulating GLP-1-mediated intestinal transit.
Collapse
Affiliation(s)
- Pernille Baumann Toft
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Hiroaki Yashiro
- Gastroenterology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Massachusetts, Cambridge, USA
| | - Derek M Erion
- Gastroenterology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Massachusetts, Cambridge, USA
| | - Matthew Paul Gillum
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Fredrik Bäckhed
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Wallenberg Laboratory, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden
- Department of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Tulika Arora
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
2
|
Kikuchi F, Ikeda Z, Kakegawa K, Nishikawa Y, Sasaki S, Fukuda K, Takami K, Banno Y, Nishikawa H, Taya N, Nakahata T, Itono S, Yashiro H, Tsuchimori K, Hiyoshi H, Sasaki M, Tohyama K, Matsumiya K, Ishihara Y, Kawamoto T, Kamaura M, Watanabe M, Kitazaki T, Maekawa T, Sasaki M. Discovery of a novel series of medium-sized cyclic enteropeptidase inhibitors. Bioorg Med Chem 2023; 93:117462. [PMID: 37683572 DOI: 10.1016/j.bmc.2023.117462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 08/28/2023] [Accepted: 08/28/2023] [Indexed: 09/10/2023]
Abstract
Enteropeptidase is located in the duodenum that involved in intestinal protein digestion. We have reported enteropeptidase inhibitors with low systemic exposure. The aim of this study was to discover novel enteropeptidase inhibitors showing more potent in vivo efficacy while retaining low systemic exposure. Inhibitory mechanism-based drug design led us to cyclize ester 2 to medium-sized lactones, showing potent enteropeptidase inhibitory activity and improving the ester stability, thus increasing fecal protein output in vivo. Optimization on the linker between two benzene rings resulted in discovery of ether lactone 6b, exhibiting further enhanced enteropeptidase inhibitory activity and long duration of inhibitory state. Oral administration of 6b in mice significantly elevated fecal protein output compared with the lead 2. In addition, 6b showed low systemic exposure along with low intestinal absorption. Furthermore, we identified the 10-membered lactonization method for scale-up synthesis of 6b, which does not require high-dilution conditions.
Collapse
Affiliation(s)
- Fumiaki Kikuchi
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
| | - Zenichi Ikeda
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Keiko Kakegawa
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Youichi Nishikawa
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Shigekazu Sasaki
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Koichiro Fukuda
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Kazuaki Takami
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshihiro Banno
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hitoaki Nishikawa
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Naohiro Taya
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Takashi Nakahata
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Sachiko Itono
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hiroaki Yashiro
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Kazue Tsuchimori
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hideyuki Hiyoshi
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masako Sasaki
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Kimio Tohyama
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Kouta Matsumiya
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Youko Ishihara
- Pharmaceutical Sciences, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tetsuji Kawamoto
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masahiro Kamaura
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masanori Watanabe
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tomoyuki Kitazaki
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tsuyoshi Maekawa
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Minoru Sasaki
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
| |
Collapse
|
3
|
Ikeda Z, Kakegawa K, Kikuchi F, Itono S, Oki H, Yashiro H, Hiyoshi H, Tsuchimori K, Hamagami K, Watanabe M, Sasaki M, Ishihara Y, Tohyama K, Kitazaki T, Maekawa T, Sasaki M. Design, Synthesis, and Biological Evaluation of a Novel Series of 4-Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low Systemic Exposure for the Treatment of Obesity. J Med Chem 2022; 65:8456-8477. [PMID: 35686954 PMCID: PMC9234964 DOI: 10.1021/acs.jmedchem.2c00463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
![]()
To discover a novel
series of potent inhibitors of enteropeptidase,
a membrane-bound serine protease localized to the duodenal brush border,
4-guanidinobenzoate derivatives were evaluated with minimal systemic
exposure. The 1c docking model enabled the installation
of an additional carboxylic acid moiety to obtain an extra interaction
with enteropeptidase, yielding 2a. The oral administration
of 2a significantly elevated the fecal protein output,
a pharmacodynamic marker, in diet-induced obese (DIO) mice, whereas
subcutaneous administration did not change this parameter. Thus, systemic
exposure of 2a was not required for its pharmacological
effects. Further optimization focusing on the in vitro IC50 value and T1/2, an indicator of dissociation
time, followed by enhanced in vivo pharmacological activity based
on the ester stability of the compounds, revealed two series of potent
enteropeptidase inhibitors, a dihydrobenzofuran analogue ((S)-5b, SCO-792) and phenylisoxazoline (6b), which exhibited potent anti-obesity effects despite their low
systemic exposure following their oral administration to DIO rats.
Collapse
Affiliation(s)
- Zenichi Ikeda
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Keiko Kakegawa
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Fumiaki Kikuchi
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Sachiko Itono
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hideyuki Oki
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hiroaki Yashiro
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hideyuki Hiyoshi
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Kazue Tsuchimori
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Kenichi Hamagami
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masanori Watanabe
- Research Division, SCOHIA PHARMA, Inc., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masako Sasaki
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Youko Ishihara
- Pharmaceutical Sciences, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Kimio Tohyama
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tomoyuki Kitazaki
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tsuyoshi Maekawa
- Research Division, SCOHIA PHARMA, Inc., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Minoru Sasaki
- Research, Takeda Pharmaceutical Company Limited, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
4
|
Ichikawa T, Ono S, Nagafuji Y, Kobayashi M, Yashiro H, Koizumi J, Uchiyama F, Fujii Y, Hasebe T, Terayama H, Hashimoto J. Congenital venous anomalies associated with retrocaval ureter: evaluation using computed tomography. Folia Morphol (Warsz) 2022; 82:300-306. [PMID: 35411547 DOI: 10.5603/fm.a2022.0036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 03/05/2022] [Accepted: 03/07/2022] [Indexed: 11/25/2022]
Abstract
BACKGROUND Retrocaval ureter is a rare congenital anomaly resulting from anomalous development of inferior vena cava (IVC) and not from anomalous of the ureter. The anomaly always occurs on the right side due to regression of right supracardinal vein and persistence of right posterior cardinal vein. Retrocaval ureter tends to be associated with various vena cava anomalies because of the embryogenesis. We aimed to identify the prevalence of associated congenital venous anomalies (CVA) resulting from cardinal vein development in adults with retrocaval ureter using computed tomography (CT) images. MATERIALS AND METHODS The study included 22 adults with retrocaval ureter. We evaluated CT findings and determined the incidence of associated CVA using thin slice data sets from CT scanner with 64 or more detectors. We compared the prevalence of CVA in the retrocaval ureter group (mean age: 57±19 years) and in the control group of 6189 adults with normal ureter (mean age: 66±14 years). RESULTS In the retrocaval ureter group, 4 adults (18.2 %) had CVA including double IVC, right double IVC, preisthmic IVC with horseshoe kidney, and preaortic iliac confluence. One of 2 adults with preaortic iliac confluence had right double right IVC. In the control group, 49 adults (0.79%) had CVA including 37 double IVCe, 11 left IVCe, and 1 IVC interruption azygos continuation. Fifteen horseshow kidneys were found. The prevalence of associated CVA in the retrocaval ureter group was higher than that in the control group (p<0.001). CONCLUSIONS Retrocaval ureter is frequently associated with CVA. Various CVA with retrocaval ureter could happen because of abnormal development of not only the right posterior or supra cardinal vein but also other cardinal veins.
Collapse
Affiliation(s)
- T Ichikawa
- Department of Radiology, Tokai University School of Medicine, Isehara-si, Japan.
| | - S Ono
- Department of Radiology, Tokai University School of Medicine, Isehara-si, Japan
| | - Y Nagafuji
- Department of Radiology, Ebina General Hospital, Ebina, Japan
| | - M Kobayashi
- Department of Radiology, Hirastuka City Hospital, Kanagawa, Japan
| | - H Yashiro
- Department of Radiology, Hirastuka City Hospital, Kanagawa, Japan
| | - J Koizumi
- Department of Radiology, Chiba University, 1-8-1 Inohana, Chuo-Ku, 260-8677 Chiba, Japan
| | - F Uchiyama
- Department of Radiology, Ebina General Hospital, Ebina, Japan
| | - Y Fujii
- Department of Radiology, Fujisawa City Hospital, Kanagawa, Japan
| | - T Hasebe
- Department of Radiology, Tokai University Hachioji Hospital, Tokyo, Japan
| | - H Terayama
- Department of Anatomy, Tokai University School of Medicine, Kanagawa, Japan
| | - J Hashimoto
- Department of Radiology, Tokai University School of Medicine, Isehara-si, Japan
| |
Collapse
|
5
|
Chen J, Martin-Mateos R, Li J, Yin Z, Chen J, Lu X, Glaser KJ, Mounajjed T, Yashiro H, Siegelman J, Winkelmann CT, Wang J, Ehman RL, Shah VH, Yin M. Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses progression and regression of steatosis, inflammation, and fibrosis in alcohol-associated liver disease. Alcohol Clin Exp Res 2021; 45:2103-2117. [PMID: 34486129 PMCID: PMC8602761 DOI: 10.1111/acer.14699] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 07/25/2021] [Accepted: 08/13/2021] [Indexed: 02/05/2023]
Abstract
BACKGROUND Magnetic resonance imaging (MRI) and MRI-based elastography (MRE) are the most promising noninvasive techniques in assessing liver diseases. The purpose of this study was to evaluate an advanced multiparametric imaging method for staging disease and assessing treatment response in realistic preclinical alcohol-associated liver disease (ALD). METHODS We utilized four different preclinical mouse models in our study: Model 1-mice were fed a fast-food diet and fructose water for 48 weeks to induce nonalcoholic fatty liver disease; Model 2-mice were fed chronic-binge ethanol (EtOH) for 10 days or 8 weeks to induce liver steatosis/inflammation. Two groups of mice were treated with interleukin-22 at different time points to induce disease regression; Model 3-mice were administered CCl4 for 2 to 4 weeks to establish liver fibrosis followed by 2 or 4 weeks of recovery; and Model 4-mice were administered EtOH plus CCl4 for 12 weeks. Mouse liver imaging biomarkers including proton density fat fraction (PDFF), liver stiffness (LS), loss modulus (LM), and damping ratio (DR) were assessed. Liver and serum samples were obtained for histologic and biochemical analyses. Ordinal logistic regression and generalized linear regression analyses were used to model the severity of steatosis, inflammation, and fibrosis, and to assess the regression of these conditions. RESULTS Multiparametric models with combinations of biomarkers (LS, LM, DR, and PDFF) used noninvasively to predict the histologic severity and regression of steatosis, inflammation, and fibrosis were highly accurate (area under the curve > 0.84 for all). A three-parameter model that incorporates LS, DR, and ALT predicted histologic fibrosis progression (r = 0.84, p < 0.0001) and regression (r = 0.79, p < 0.0001) as measured by collagen content in livers. CONCLUSION This preclinical study provides evidence that multiparametric MRI/MRE can be used noninvasively to assess disease severity and monitor treatment response in ALD.
Collapse
Affiliation(s)
- Jingbiao Chen
- The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
- Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
| | - Rosa Martin-Mateos
- Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
- Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - Jiahui Li
- Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Ziying Yin
- Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Jie Chen
- Radiology, Mayo Clinic, Rochester, Minnesota, USA
- Department of Radiology, West China Hospital, Chengdu, China
| | - Xin Lu
- Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | | | | | - Hiroaki Yashiro
- Research and Development, Takeda Pharmaceuticals International Co., Cambridge, MA, USA
| | - Jenifer Siegelman
- Research and Development, Takeda Pharmaceuticals International Co., Cambridge, MA, USA
| | | | - Jin Wang
- The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
| | | | - Vijay H. Shah
- Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
| | - Meng Yin
- Radiology, Mayo Clinic, Rochester, Minnesota, USA
| |
Collapse
|
6
|
Tamura YO, Sugama J, Iwasaki S, Sasaki M, Yasuno H, Aoyama K, Watanabe M, Erion DM, Yashiro H. Selective acetyl-CoA carboxylase 1 inhibitor improves hepatic steatosis and hepatic fibrosis in a pre-clinical NASH model. J Pharmacol Exp Ther 2021; 379:280-289. [PMID: 34535562 DOI: 10.1124/jpet.121.000786] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 09/14/2021] [Indexed: 11/22/2022] Open
Abstract
Acetyl-CoA carboxylase (ACC) 1 and ACC2 are essential rate-limiting enzymes that synthesize malonyl-CoA (M-CoA) from acetyl-CoA. ACC1 is predominantly expressed in lipogenic tissues and regulates the de novo lipogenesis (DNL) flux. It is upregulated in the liver of patients with nonalcoholic fatty liver disease (NAFLD), ultimately leading to the formation of fatty liver. Therefore, selective ACC1 inhibitors may prevent the pathophysiology of NAFLD and nonalcoholic steatohepatitis (NASH) by reducing hepatic fat, inflammation, and fibrosis. Many studies have suggested ACC1/2 dual inhibitors for treating NAFLD/NASH; however, reports on selective ACC1 inhibitors are lacking. In this study, we investigated the effects of compound-1, a selective ACC1 inhibitor for treating NAFLD/NASH, using pre-clinical in vitro and in vivo models. Compound-1 reduced M-CoA content and inhibited the incorporation of [14C] acetate into fatty acids in HepG2 cells. Additionally, it reduced hepatic M-CoA content and inhibited DNL in C57BL/6J mice after a single dose. Further, compound-1 treatment for 8 weeks in western diet-fed melanocortin 4 receptor (MC4R) knockout mice-NAFLD/NASH mouse model-improved liver hypertrophy and reduced hepatic triglyceride content. The reduction of hepatic M-CoA by the selective ACC1 inhibitor was highly correlated with reduction in hepatic steatosis and fibrosis. These findings support further investigations of the use of this ACC1 inhibitor as a new treatment for NFLD/NASH. Significance Statement This is the first study to demonstrate that a novel selective inhibitor of acetyl-CoA carboxylase 1 (ACC1) has anti-nonalcoholic fatty liver disease (NAFLD) and anti-nonalcoholic steatohepatitis (NASH) effects in pre-clinical models. Treatment with this compound significantly improved hepatic steatosis and fibrosis in a mouse model. These findings support the use of this ACC1 inhibitor as a new treatment for NAFLD/NASH.
Collapse
Affiliation(s)
- Yumiko Okano Tamura
- Strategy Planning Office, Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Japan
| | | | | | | | | | | | | | - Derek M Erion
- Takeda Pharmaceutical Company Limited, United States
| | | |
Collapse
|
7
|
Sugama J, Moritoh Y, Yashiro H, Tsuchimori K, Watanabe M. Enteropeptidase inhibition improves obesity by modulating gut microbiota composition and enterobacterial metabolites in diet-induced obese mice. Pharmacol Res 2021; 163:105337. [PMID: 33276106 DOI: 10.1016/j.phrs.2020.105337] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2020] [Revised: 11/05/2020] [Accepted: 11/25/2020] [Indexed: 12/19/2022]
Abstract
Enteropeptidase is a transmembrane serine protease localized in the lumen of the duodenum that acts as a key enzyme for protein digestion. SCO-792 is an orally available enteropeptidase inhibitor that has been reported to have therapeutic effects on obesity and diabetes in mice. However, the mechanism underlying the therapeutic effect of SCO-792 has not yet been fully elucidated. In this study, we evaluated the role of gut microbiota on SCO-792-induced body weight (BW) reduction in high-fat diet-induced obese (DIO) mice. Chronic administration of SCO-792 substantially decreased BW and food intake in DIO mice. While the pair-fed study uncovered food intake-independent mechanisms of BW reduction by SCO-792. Interestingly, antibiotics-induced microbiota elimination in the gut canceled SCO-792-induced BW reduction by nearly half without affecting the anorectic effect, indicating the involvement of gut microbiota in the anti-obesity mechanism that is independent of food intake reduction. Microbiome analysis revealed that SCO-792 altered the gut microbiota composition in DIO mice. Notably, it was found that the abundance of Firmicutes decreased while that of Verrucomicrobia increased at the phylum level. Increased abundance of Akkermansia muciniphila, a bacterium known to be useful for host metabolism, was observed in SCO-792-treated mice. Fecal metabolome analysis revealed increased amino acid levels, indicating gut enteropeptidase inhibition. In addition, SCO-792 was found to increase the level of short-chain fatty acids, including propionate, and bile acids in the feces, which all help maintain gut health and improve metabolism. Furthermore, it was found that SCO-792 induced the elevation of colonic immunoglobulin A (IgA) concentration, which may maintain the microbiota condition, in DIO mice. In conclusion, this study demonstrates the contribution of microbiota to SCO-792-induced BW reduction. Enteropeptidase-mediated regulation of microbiota, enterobacterial metabolites, and IgA in the gut may coordinately drive the therapeutic effects of SCO-792 in obesity.
Collapse
Affiliation(s)
- Jun Sugama
- Research and Development Division, SCOHIA PHARMA Inc., Kanagawa, Japan.
| | - Yusuke Moritoh
- Research and Development Division, SCOHIA PHARMA Inc., Kanagawa, Japan.
| | - Hiroaki Yashiro
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Kazue Tsuchimori
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Masanori Watanabe
- Research and Development Division, SCOHIA PHARMA Inc., Kanagawa, Japan.
| |
Collapse
|
8
|
Shepherd EL, Saborano R, Northall E, Matsuda K, Ogino H, Yashiro H, Pickens J, Feaver RE, Cole BK, Hoang SA, Lawson MJ, Olson M, Figler RA, Reardon JE, Nishigaki N, Wamhoff BR, Günther UL, Hirschfield G, Erion DM, Lalor PF. Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. JHEP Rep 2020; 3:100217. [PMID: 33490936 PMCID: PMC7807164 DOI: 10.1016/j.jhepr.2020.100217] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Revised: 10/30/2020] [Accepted: 11/08/2020] [Indexed: 02/07/2023] Open
Abstract
Background & Aims Increasing evidence highlights dietary fructose as a major driver of non-alcoholic fatty liver disease (NAFLD) pathogenesis, the majority of which is cleared on first pass through the hepatic circulation by enzymatic phosphorylation to fructose-1-phosphate via the ketohexokinase (KHK) enzyme. Without a current approved therapy, disease management emphasises lifestyle interventions, but few patients adhere to such strategies. New targeted therapies are urgently required. Methods We have used a unique combination of human liver specimens, a murine dietary model of NAFLD and human multicellular co-culture systems to understand the hepatocellular consequences of fructose administration. We have also performed a detailed nuclear magnetic resonance-based metabolic tracing of the fate of isotopically labelled fructose upon administration to the human liver. Results Expression of KHK isoforms is found in multiple human hepatic cell types, although hepatocyte expression predominates. KHK knockout mice show a reduction in serum transaminase, reduced steatosis and altered fibrogenic response on an Amylin diet. Human co-cultures exposed to fructose exhibit steatosis and activation of lipogenic and fibrogenic gene expression, which were reduced by pharmacological inhibition of KHK activity. Analysis of human livers exposed to 13C-labelled fructose confirmed that steatosis, and associated effects, resulted from the accumulation of lipogenic precursors (such as glycerol) and enhanced glycolytic activity. All of these were dose-dependently reduced by administration of a KHK inhibitor. Conclusions We have provided preclinical evidence using human livers to support the use of KHK inhibition to improve steatosis, fibrosis, and inflammation in the context of NAFLD. Lay summary We have used a mouse model, human cells, and liver tissue to test how exposure to fructose can cause the liver to store excess fat and become damaged and scarred. We have then inhibited a key enzyme within the liver that is responsible for fructose metabolism. Our findings show that inhibition of fructose metabolism reduces liver injury and fibrosis in mouse and human livers and thus this may represent a potential route for treating patients with fatty liver disease in the future.
Collapse
Key Words
- ALD, alcohol-related cirrhosis
- ALT, alanine transaminase
- APRI, AST to Platelet Ratio Index
- AST, aspartate transaminase
- BEC, biliary epithelial cells
- BSA, bovine serum albumin
- CT, computed tomography
- DNL, de novo lipogenesis
- FIB4, fibrosis-4
- Fibrosis
- Fructose
- G/F, glucose/fructose
- HSCs, hepatic stellate cells
- HSECs, hepatic sinusoidal endothelial cells
- HSQC, heteronuclear single quantum coherence
- IGF, insulin-like growth factor
- KHK, ketohexokinase
- KO, knockout
- LGLI, low glucose and insulin
- Metabolism
- NAFLD
- NAFLD, non-alcoholic fatty liver disease
- NASH
- NASH, non-alcoholic steatohepatitis
- NPCs, non-parenchymal cells
- PBC, primary biliary cholangitis
- PDGF, platelet-derived growth factor
- PSC, primary sclerosing cholangitis
- TG, triglyceride
- TGFB, transforming growth factor beta
- TIMP-1, Tissue Inhibitor of Matrix metalloproteinase-1
- Treatment
- WT, wild-type
- aLMF, activated liver myofibroblasts
Collapse
Affiliation(s)
- Emma L Shepherd
- Centre for Liver and Gastroenterology Research and National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
| | - Raquel Saborano
- Centre for Liver and Gastroenterology Research and National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
| | - Ellie Northall
- Centre for Liver and Gastroenterology Research and National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
| | - Kae Matsuda
- Takeda Pharmaceuticals Cardiovascular and Metabolic Drug Discovery Unit, Kanagawa, Japan
| | - Hitomi Ogino
- Takeda Pharmaceuticals Cardiovascular and Metabolic Drug Discovery Unit, Kanagawa, Japan
| | - Hiroaki Yashiro
- Takeda Pharmaceuticals Gastroenterology Drug Discovery Unit, Cambridge, MA, USA
| | - Jason Pickens
- Takeda Pharmaceuticals Gastroenterology Drug Discovery Unit, Cambridge, MA, USA
| | | | | | | | | | | | | | | | - Nobuhiro Nishigaki
- Takeda Pharmaceuticals Cardiovascular and Metabolic Drug Discovery Unit, Kanagawa, Japan
| | | | - Ulrich L Günther
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
| | - Gideon Hirschfield
- Centre for Liver and Gastroenterology Research and National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.,Toronto Centre for Liver Disease, University of Toronto, Toronto General Hospital, Toronto, Canada
| | - Derek M Erion
- Takeda Pharmaceuticals Gastroenterology Drug Discovery Unit, Cambridge, MA, USA
| | - Patricia F Lalor
- Centre for Liver and Gastroenterology Research and National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
| |
Collapse
|
9
|
Matsumoto M, Yashiro H, Ogino H, Aoyama K, Nambu T, Nakamura S, Nishida M, Wang X, Erion DM, Kaneko M. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis. PLoS One 2020; 15:e0228212. [PMID: 31990961 PMCID: PMC6986730 DOI: 10.1371/journal.pone.0228212] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Accepted: 01/10/2020] [Indexed: 12/16/2022] Open
Abstract
Acetyl-CoA carboxylase (ACC) catalyzes the rate-limiting step in de novo lipogenesis, which is increased in the livers of patients with nonalcoholic steatohepatitis. GS-0976 (firsocostat), an inhibitor of isoforms ACC1 and ACC2, reduced hepatic steatosis and serum fibrosis biomarkers such as tissue inhibitor of metalloproteinase 1 in patients with nonalcoholic steatohepatitis in a randomized controlled trial, although the impact of this improvement on fibrosis has not fully been evaluated in preclinical models. Here, we used Western diet-fed melanocortin 4 receptor-deficient mice that have similar phenotypes to nonalcoholic steatohepatitis patients including progressively developed hepatic steatosis as well as fibrosis. We evaluated the effects of ACC1/2 inhibition on hepatic fibrosis. After the confirmation of significant hepatic fibrosis with a 13-week pre-feeding, GS-0976 (4 and 16 mg/kg/day) treatment for 9 weeks lowered malonyl-CoA and triglyceride content in the liver and improved steatosis, histologically. Furthermore, GS-0976 reduced the histological area of hepatic fibrosis, hydroxyproline content, mRNA expression level of type I collagen in the liver, and plasma tissue metalloproteinase inhibitor 1, suggesting an improvement of hepatic fibrosis. The treatment with GS-0976 was also accompanied by reductions of plasma ALT and AST levels. These data demonstrate that improvement of hepatic lipid metabolism by ACC1/2 inhibition could be a new option to suppress fibrosis progression as well as to improve hepatic steatosis in nonalcoholic steatohepatitis.
Collapse
Affiliation(s)
- Mitsuharu Matsumoto
- Department of Integrated Biology, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
- * E-mail:
| | - Hiroaki Yashiro
- Gastroenterology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, United States of America
| | - Hitomi Ogino
- Department of Integrated Biology, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
| | - Kazunobu Aoyama
- Department of Drug Disposition & Analysis, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
| | - Tadahiro Nambu
- Department of Nonclinical Safety Research, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
| | - Sayuri Nakamura
- Department of Nonclinical Safety Research, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
| | - Mayumi Nishida
- Department of Integrated Biology, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
| | - Xiaolun Wang
- Gastroenterology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, United States of America
| | - Derek M. Erion
- Gastroenterology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, United States of America
| | - Manami Kaneko
- Department of Integrated Biology, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
| |
Collapse
|
10
|
Yashiro H, Hamagami K, Hiyoshi H, Sugama J, Tsuchimori K, Yamaguchi F, Moritoh Y, Sasaki M, Maekawa T, Yamada Y, Watanabe M. SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice. Diabetes Obes Metab 2019; 21:2228-2239. [PMID: 31144422 PMCID: PMC6771630 DOI: 10.1111/dom.13799] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 05/22/2019] [Accepted: 05/28/2019] [Indexed: 12/23/2022]
Abstract
AIMS Enteropeptidase is a serine protease localized on the duodenal brush border that catalyzes the conversion of inactive trypsinogen into active trypsin, thereby regulating protein breakdown in the gut. We evaluated the effects of SCO-792, a novel enteropeptidase inhibitor, in mice. MATERIALS AND METHODS In vivo inhibition of enteropeptidase was evaluated via an oral protein challenge. Pharmacological effects were evaluated in normal mice, in diet-induced obese (DIO) mice and in obese and diabetic ob/ob mice. RESULTS A single oral administration of SCO-792 inhibited plasma branched-chain amino acids (BCAAs) in an oral protein challenge test in mice, indicating in vivo inhibition of enteropeptidase. Repeated treatment with SCO-792 induced reduction in food intake and decrease in body weight in DIO and ob/ob mice. Plasma FGF21 levels were increased in SCO-792-treated DIO mice, an observation that was probably independent of reduction in food intake. Hyperglycaemia was markedly improved in SCO-792-treated ob/ob mice. A hyperinsulinaemic-euglycaemic clamp study revealed improved muscle insulin sensitivity in SCO-792-treated ob/ob mice. SCO-792 also improved plasma and liver lipid profiles and decreased plasma alanine transaminase, suggesting a potential treatment for liver diseases. Dietary supplementation with essential amino acids attenuated the effect of SCO-792 on reduction in food intake and decrease in body weight in normal mice, suggesting a pivotal role for enteropeptidase in these biological phenomena. CONCLUSIONS SCO-792 inhibited enteropeptidase in vivo, reduced food intake, decreased body weight, increased insulin sensitivity, improved glucose and lipid control, and ameliorated liver parameters in mouse models with obesity and/or diabetes. SCO-792 may exhibit similar effects in patients.
Collapse
Affiliation(s)
- Hiroaki Yashiro
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company LimitedKanagawaJapan
| | - Kenichi Hamagami
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company LimitedKanagawaJapan
| | - Hideyuki Hiyoshi
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company LimitedKanagawaJapan
| | - Jun Sugama
- Research and Development DivisionSCOHIA PHARMA, Inc.KanagawaJapan
| | - Kazue Tsuchimori
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company LimitedKanagawaJapan
| | | | - Yusuke Moritoh
- Research and Development DivisionSCOHIA PHARMA, Inc.KanagawaJapan
| | - Minoru Sasaki
- Pharmaceutical Research DivisionTakeda Pharmaceutical Company LimitedKanagawaJapan
| | - Tsuyoshi Maekawa
- Research and Development DivisionSCOHIA PHARMA, Inc.KanagawaJapan
| | - Yukio Yamada
- Research and Development DivisionSCOHIA PHARMA, Inc.KanagawaJapan
| | | |
Collapse
|
11
|
Sasaki M, Miyahisa I, Itono S, Yashiro H, Hiyoshi H, Tsuchimori K, Hamagami K, Moritoh Y, Watanabe M, Tohyama K, Sasaki M, Sakamoto J, Kawamoto T. Discovery and characterization of a small-molecule enteropeptidase inhibitor, SCO-792. Pharmacol Res Perspect 2019; 7:e00517. [PMID: 31508234 PMCID: PMC6726858 DOI: 10.1002/prp2.517] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Revised: 07/19/2019] [Accepted: 07/26/2019] [Indexed: 12/11/2022] Open
Abstract
Enteropeptidase, localized into the duodenum brush border, is a key enzyme catalyzing the conversion of pancreatic trypsinogen proenzyme to active trypsin, thereby regulating protein digestion and energy homeostasis. We report the discovery and pharmacological profiles of SCO-792, a novel inhibitor of enteropeptidase. A screen employing fluorescence resonance energy transfer was performed to identify enteropeptidase inhibitors. Inhibitory profiles were determined by in vitro assays. To evaluate the in vivo inhibitory effect on protein digestion, an oral protein challenge test was performed in rats. Our screen identified a series of enteropeptidase inhibitors, and compound optimization resulted in identification of SCO-792, which inhibited enteropeptidase activity in vitro, with IC 50 values of 4.6 and 5.4 nmol/L in rats and humans, respectively. In vitro inhibition of enteropeptidase by SCO-792 was potentiated by increased incubation time, and the calculated Kinact/KI was 82 000/mol/L s. An in vitro dissociation assay showed that SCO-792 had a dissociation half-life of almost 14 hour, with a calculated koff rate of 0.047/hour, which suggested that SCO-792 is a reversible enteropeptidase inhibitor. In normal rats, a ≤4 hour prior oral dose of SCO-792 effectively inhibited plasma elevation of branched-chain amino acids in an oral protein challenge test, which indicated that SCO-792 effectively inhibited protein digestion in vivo. In conclusion, our new screen system identified SCO-792 as a potent and reversible inhibitor against enteropeptidase. SCO-792 slowly dissociated from enteropeptidase in vitro and inhibited protein digestion in vivo. Further study using SCO-792 could reveal the effects of inhibiting enteropeptidase on biological actions.
Collapse
Affiliation(s)
- Masako Sasaki
- ResearchTakeda Pharmaceutical Company LimitedFujisawaKanagawaJapan
| | - Ikuo Miyahisa
- ResearchTakeda Pharmaceutical Company LimitedFujisawaKanagawaJapan
| | - Sachiko Itono
- ResearchTakeda Pharmaceutical Company LimitedFujisawaKanagawaJapan
- Present address:
Axcelead Drug Discovery Partners, Inc.FujisawaKanagawaJapan
| | - Hiroaki Yashiro
- ResearchTakeda Pharmaceutical Company LimitedFujisawaKanagawaJapan
| | - Hideyuki Hiyoshi
- ResearchTakeda Pharmaceutical Company LimitedFujisawaKanagawaJapan
| | - Kazue Tsuchimori
- ResearchTakeda Pharmaceutical Company LimitedFujisawaKanagawaJapan
| | | | | | | | - Kimio Tohyama
- ResearchTakeda Pharmaceutical Company LimitedFujisawaKanagawaJapan
| | - Minoru Sasaki
- ResearchTakeda Pharmaceutical Company LimitedFujisawaKanagawaJapan
| | - Jun‐ichi Sakamoto
- ResearchTakeda Pharmaceutical Company LimitedFujisawaKanagawaJapan
- Present address:
Axcelead Drug Discovery Partners, Inc.FujisawaKanagawaJapan
| | - Tomohiro Kawamoto
- ResearchTakeda Pharmaceutical Company LimitedFujisawaKanagawaJapan
- Present address:
Axcelead Drug Discovery Partners, Inc.FujisawaKanagawaJapan
| |
Collapse
|
12
|
Hirose H, Yamasaki T, Ogino M, Mizojiri R, Tamura-Okano Y, Yashiro H, Muraki Y, Nakano Y, Sugama J, Hata A, Iwasaki S, Watanabe M, Maekawa T, Kasai S. Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus. Bioorg Med Chem 2017. [PMID: 28642028 DOI: 10.1016/j.bmc.2017.06.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Somatostatin receptor subtype 5 (SSTR5) has emerged as a novel attractive drug target for type 2 diabetes mellitus. Starting from N-benzyl azetidine derivatives 1 and 2 as in-house hit compounds, we explored the introduction of a carboxyl group into the terminal benzene of 1 to enhance SSTR5 antagonistic activity by the combination of the substituents at the 3-position of the isoxazoline. Incorporation of a carboxyl group at the 4-position of the benzene ring resulted in a significant enhancement in potency, however, the 4-benzoic acid derivative 10c exhibited moderate human ether-a-go-go related gene (hERG) inhibitory activity. A subsequent optimization study revealed that replacement of the 4-benzoic acid with an isonipecotic acid dramatically reduced hERG inhibition (5.6% inhibition at 30μM) by eliminating π-related interaction with hERG K+ channel, which resulted in the identification of 1-(2-((2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl)-5-oxa-2,6-diazaspiro[3.4]oct-6-en-7-yl)piperidin-4-carboxylic acid 25a (hSSTR5/mSSTR5 IC50=9.6/57nM). Oral administration of 25a in high-fat diet fed C57BL/6J mice augmented insulin secretion in a glucose-dependent manner and lowered blood glucose concentration.
Collapse
Affiliation(s)
- Hideki Hirose
- Research Division Medicinal Chemistry Laboratory, SCOHIA PHARMA, Inc., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan.
| | - Takeshi Yamasaki
- Research Division, Takeda Pharmaceutical Co., Ltd., Shonan Research Center, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masaki Ogino
- Research Division Medicinal Chemistry Laboratory, SCOHIA PHARMA, Inc., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Ryo Mizojiri
- Research Division, Takeda Pharmaceutical Co., Ltd., Shonan Research Center, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yumiko Tamura-Okano
- Research Division, Takeda Pharmaceutical Co., Ltd., Shonan Research Center, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hiroaki Yashiro
- Research Division, Takeda Pharmaceutical Co., Ltd., Shonan Research Center, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yo Muraki
- Research Division, Takeda Pharmaceutical Co., Ltd., Shonan Research Center, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshihide Nakano
- Global Procurement, Takeda Pharmaceutical Co., Ltd., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Jun Sugama
- Research Division Medicinal Chemistry Laboratory, SCOHIA PHARMA, Inc., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Akito Hata
- Research Division, Takeda Pharmaceutical Co., Ltd., Shonan Research Center, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Shinji Iwasaki
- Research Division, Takeda Pharmaceutical Co., Ltd., Shonan Research Center, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masanori Watanabe
- Research Division Medicinal Chemistry Laboratory, SCOHIA PHARMA, Inc., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tsuyoshi Maekawa
- Research Division Medicinal Chemistry Laboratory, SCOHIA PHARMA, Inc., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Shizuo Kasai
- Research Division Medicinal Chemistry Laboratory, SCOHIA PHARMA, Inc., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
13
|
Yashiro H, Takagahara S, Tamura YO, Miyahisa I, Matsui J, Suzuki H, Ikeda S, Watanabe M. A Novel Selective Inhibitor of Delta-5 Desaturase Lowers Insulin Resistance and Reduces Body Weight in Diet-Induced Obese C57BL/6J Mice. PLoS One 2016; 11:e0166198. [PMID: 27832159 PMCID: PMC5104425 DOI: 10.1371/journal.pone.0166198] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2016] [Accepted: 10/24/2016] [Indexed: 11/15/2022] Open
Abstract
Obesity is now recognized as a state of chronic low-grade inflammation and is called as metabolic inflammation. Delta-5 desaturase (D5D) is an enzyme that metabolizes dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA). Thus, D5D inhibition increases DGLA (precursor to anti-inflammatory eicosanoids) while decreasing AA (precursor to pro-inflammatory eicosanoids), and could result in synergistic improvement in the low-grade inflammatory state. Here, we demonstrate reduced insulin resistance and the anti-obesity effect of a D5D selective inhibitor (compound-326), an orally active small-molecule, in a high-fat diet-induced obese (DIO) mouse model. In vivo D5D inhibition was confirmed by determining changes in blood AA/DGLA profiles. In DIO mice, chronic treatment with compound-326 lowered insulin resistance and caused body weight loss without significant impact on cumulative calorie intake. Decreased macrophage infiltration into adipose tissue was expected from mRNA analysis. Increased daily energy expenditure was also observed following administration of compound-326, in line with sustained body weight loss. These data indicate that the novel D5D selective inhibitor, compound-326, will be a new class of drug for the treatment of obese and diabetic patients.
Collapse
Affiliation(s)
- Hiroaki Yashiro
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa Japan
- * E-mail:
| | - Shuichi Takagahara
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa Japan
| | - Yumiko Okano Tamura
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa Japan
| | - Ikuo Miyahisa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa Japan
| | - Junji Matsui
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa Japan
| | - Hideo Suzuki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa Japan
| | - Shota Ikeda
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa Japan
| | - Masanori Watanabe
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa Japan
| |
Collapse
|
14
|
Nakatsuka S, Inoue M, Tsukada J, Oguro S, Yashiro H, Kuribayashi S. Ethanol ablation of persistent bile leakage from isolated bile ducts after hepatobiliary surgery. J Vasc Interv Radiol 2014. [DOI: 10.1016/j.jvir.2013.12.492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
15
|
Terao Y, Suzuki H, Yoshikawa M, Yashiro H, Takekawa S, Fujitani Y, Okada K, Inoue Y, Yamamoto Y, Nakagawa H, Yao S, Kawamoto T, Uchikawa O. Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors. Bioorg Med Chem Lett 2012; 22:7326-9. [PMID: 23147077 DOI: 10.1016/j.bmcl.2012.10.084] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2012] [Revised: 10/16/2012] [Accepted: 10/17/2012] [Indexed: 11/19/2022]
Abstract
Imidazo[1,2-a]pyridine derivatives were designed, synthesized, and evaluated as inhibitors of the apoptosis signal-regulating kinase 1 (ASK1). These were based on a benzothiazole derivative that was discovered from high-throughput screening of our compound library. As a result, we identified potent, selective, and orally bioavailable ASK1 inhibitors for wide range of therapeutic targets.
Collapse
Affiliation(s)
- Yoshito Terao
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Yamauchi Y, Izumi Y, Hashimoto K, Yashiro H, Inoue M, Nakatsuka S, Kawamura M, Nomori H. Palliative percutaneous cryoablation in a patient with locally advanced invasive thymoma. Eur Respir J 2012; 39:505-7. [DOI: 10.1183/09031936.00072211] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
17
|
Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PRV, Rorsman P. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther 2011; 340:483-9. [PMID: 22106100 DOI: 10.1124/jpet.111.187708] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
G protein-coupled receptor 40 (GPR40)/free fatty acid 1 (FFA1) is a G protein-coupled receptor involved in free fatty acid-induced insulin secretion. To analyze the effect of our novel GPR40/FFA1-selective agonist, [(3S)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemi-hydrate (TAK-875), on insulin and glucagon secretion, we performed hormone secretion assays and measured intracellular Ca²⁺ concentration ([Ca²⁺](i)) in both human and rat islets. Insulin and glucagon secretion were measured in static and dynamic conditions by using groups of isolated rat and human pancreatic islets. [Ca²⁺](i) was recorded by using confocal microscopy. GPR40/FFA1 expression was measured by quantitative polymerase chain reaction. In both human and rat islets, TAK-875 enhanced glucose-induced insulin secretion in a glucose-dependent manner. The stimulatory effect of TAK-875 was similar to that produced by glucagon-like peptide-1 and correlated with the elevation of β-cell [Ca²⁺](i). TAK-875 was without effect on glucagon secretion at both 1 and 16 mM glucose in human islets. These data indicate that GPR40/FFA1 influences mainly insulin secretion in a glucose-dependent manner. The β-cell-specific action of TAK-875 in human islets may represent a therapeutically useful feature that allows plasma glucose control without compromising counter-regulation of glucagon secretion, thus minimizing the risk of hypoglycemia.
Collapse
Affiliation(s)
- Hiroaki Yashiro
- Metabolic Disease Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85 Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan.
| | | | | | | | | | | |
Collapse
|
18
|
Miyamoto Y, Banno Y, Yamashita T, Fujimoto T, Oi S, Moritoh Y, Asakawa T, Kataoka O, Yashiro H, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Tsubotani S, Tani A, Sasaki M, Funami M, Amano M, Yamamoto Y, Aertgeerts K, Yano J, Maezaki H. Discovery of a 3-Pyridylacetic Acid Derivative (TAK-100) as a Potent, Selective and Orally Active Dipeptidyl Peptidase IV (DPP-4) Inhibitor. J Med Chem 2011; 54:831-50. [DOI: 10.1021/jm101236h] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Yasufumi Miyamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Yoshihiro Banno
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Tohru Yamashita
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Tatsuhiko Fujimoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Satoru Oi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Yusuke Moritoh
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Tomoko Asakawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Osamu Kataoka
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Hiroaki Yashiro
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Koji Takeuchi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Nobuhiro Suzuki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Koji Ikedo
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Takuo Kosaka
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Shigetoshi Tsubotani
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Akiyoshi Tani
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Masako Sasaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Miyuki Funami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Michiko Amano
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Yoshio Yamamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Kathleen Aertgeerts
- Takeda San Diego, Inc., 10410, Science Center Drive, San Diego, California 92121, United States
| | - Jason Yano
- Takeda San Diego, Inc., 10410, Science Center Drive, San Diego, California 92121, United States
| | - Hironobu Maezaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| |
Collapse
|
19
|
Minami T, Kobayashi S, Mizuuchi T, Yashiro H, Takeuchi M, Ohshima S, Yamamoto S, Okada H, Nagasaki K, Nakamura Y, Hanatani K, Konoshima S, Sano F. Design of a new high repetition rate Nd:YAG Thomson scattering system for Heliotron J. Rev Sci Instrum 2010; 81:10D532. [PMID: 21033887 DOI: 10.1063/1.3496977] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
A new high repetition rate Nd:YAG Thomson scattering system has been designed for the Heliotron J helical device. The main purpose of installing the new Thomson scattering system is an investigation of an improved confinement physics such as the edge transport barrier (H-mode) or the internal transport barrier of the helical plasma. The system has 25 spatial points with ∼10 mm resolution. Two high repetition Nd:YAG lasers (>550 mJ at 50 Hz) realize the measurement of the time evolution of the plasma profile with 10 ms time interval. Scattered light is collected with a large concave mirror (D=800 mm, f/2.25) with a solid angle of ∼100 msr. The laser beam is injected from obliquely downward to upward, and obliquely backscattered light is detected (scattering angle is 20°). Model simulation of the polychromator shows the measurable electron temperature and density range are from 10 eV to 10 keV, >5×10(18) m(-3) within 3% error for the temperature measurement, respectively.
Collapse
Affiliation(s)
- Takashi Minami
- Institute of Advancaed Energy, Kyoto University, Gokasho, Uji 611-0011, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Yamauchi Y, Kawamura M, Nakatsuka S, Izumi Y, Yashiro H, Tsukada N, Inoue M, Nomori H. Percutaneous cryoablation for primary lung cancer: Outcome and prospective future. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e17515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Yamauchi Y, Kawamura M, Nakatsuka S, Izumi Y, Yashiro H, Tsukada N, Inoue M, Kuribayashi S, Nomori H. Abstract No. 349: Cryoablation for lung metastasis of colorectal cancer: Outcome and prospective future. J Vasc Interv Radiol 2010. [DOI: 10.1016/j.jvir.2009.12.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
22
|
Yamauchi Y, Izumi Y, Tsukada N, Asakura K, Inoue M, Yashiro H, Nakatsuka S, Kawamura M. Assessment of the safety and efficacy of percutaneous cryoablation for lung tumors. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7592 Background: Percutaneous cryoablation using high resolution fluoroscopic CT guidance under local anesthesia offers a potential tool for local control of lung tumors in combination with systemic treatments. In this study, we retrospectively analyzed the safety, and efficacy of percutaneous cryoablation for lung tumors (PCLT). Methods: This study was approved by the institutional review board. From October 2002, PCLT was performed in patients who either did not oncologically fulfill the indications for resection, or refused resection. CT scan was examined every 3 months after PCLT. >20% increase in the treated lesion size was diagnosed as local failure. Survival analysis was done by Kaplan-Meier. Results: There were 147 patients (95 male, 52 female, mean age 60, 20 primary lung cancer, metastases; 29 of lung cancer, 35 of colorectal cancer, 63 of other sites). 251 sessions were done for 462 tumors. Mean tumor diameter was 18.3mm. PCLT was well tolerated in most patients. In 1 case, broncho-thoracic fistula occurred in the treated region which lead to empyema. Other complications were pneumothorax (153 sessions, 61%, chest tube required in 23 sessions), pleural effusion (160 sessions, 64%), and transient hemoptysis (82 sessions, 33%). Overall one- and two-year local control rates were 81.0% and 59.1%, respectively. Overall one- and two-year survival rates were 80.0% and 54.5%, respectively. In the 1–20 mm sized (n=362) vs. over 21mm sized (n=100) lesions, the local control rates at one year were 84% vs. 56% (p=0.0007), and at two years were 63% vs. 35% (p=0.017), respectively. There were no differences in local control between primary and metastatic tumors, carcinomas and sarcomas. Survival of patients whose lesions were limited to 1–20mm (n=89) was prolonged vs. those who had at least one over 21mm lesion (n=58) (p=0.01). However, one, and two-year survival rates did not differ significantly between these groups (one-year; 85.5% vs. 71.7% (p=0.07), two-year; 60.7% vs. 46.5% (p=0.16)). Conclusions: PCLT was minimally invasive and safe. 1–20mm tumors were good candidates. Contribution of PCLT to survival was not clear in this mixed patient population. To improve local control in over 20 mm tumors, we are computer simulating freezing kinetics to optimize the number and the positioning of the probes. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Yamauchi
- Keio University School of Medicine, Tokyo, Japan; Kawasaki Municipal Hospital, Kawasaki, Japan; Hiratsuka City Hospital, Hiratsuka, Japan
| | - Y. Izumi
- Keio University School of Medicine, Tokyo, Japan; Kawasaki Municipal Hospital, Kawasaki, Japan; Hiratsuka City Hospital, Hiratsuka, Japan
| | - N. Tsukada
- Keio University School of Medicine, Tokyo, Japan; Kawasaki Municipal Hospital, Kawasaki, Japan; Hiratsuka City Hospital, Hiratsuka, Japan
| | - K. Asakura
- Keio University School of Medicine, Tokyo, Japan; Kawasaki Municipal Hospital, Kawasaki, Japan; Hiratsuka City Hospital, Hiratsuka, Japan
| | - M. Inoue
- Keio University School of Medicine, Tokyo, Japan; Kawasaki Municipal Hospital, Kawasaki, Japan; Hiratsuka City Hospital, Hiratsuka, Japan
| | - H. Yashiro
- Keio University School of Medicine, Tokyo, Japan; Kawasaki Municipal Hospital, Kawasaki, Japan; Hiratsuka City Hospital, Hiratsuka, Japan
| | - S. Nakatsuka
- Keio University School of Medicine, Tokyo, Japan; Kawasaki Municipal Hospital, Kawasaki, Japan; Hiratsuka City Hospital, Hiratsuka, Japan
| | - M. Kawamura
- Keio University School of Medicine, Tokyo, Japan; Kawasaki Municipal Hospital, Kawasaki, Japan; Hiratsuka City Hospital, Hiratsuka, Japan
| |
Collapse
|
23
|
Ito T, Yashiro H, Yamase T. Polyoxometalate Langmuir–Blodgett films toward two-dimensional molecular crystals. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308082032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
24
|
Kimura S, Yashiro H, Okunishi K, Hagiwara M, He Z, Kindo K, Taniyama T, Itoh M. Field-induced order-disorder transition in antiferromagnetic BaCo(2)V(2)O(8) driven by a softening of spinon excitation. Phys Rev Lett 2007; 99:087602. [PMID: 17930982 DOI: 10.1103/physrevlett.99.087602] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/16/2007] [Indexed: 05/25/2023]
Abstract
High field magnetization and ESR measurements on the quasi-one-dimensional (1D) antiferromagnet BaCo(2)V(2)O(8) have been performed in magnetic fields up to 50 T along the chain. The experimental results are explained well in terms of a 1D S=1/2 antiferromagnetic XXZ model in longitudinal fields. We show that the quantum phase transition from the Néel ordered phase to the spin liquid one in the model is responsible for a peculiar order to disorder transition in BaCo(2)V(2)O(8).
Collapse
Affiliation(s)
- S Kimura
- KYOKUGEN, Osaka University, Machikaneyama 1-3, Toyanaka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Kimura S, Hagiwara M, Ueda H, Narumi Y, Kindo K, Yashiro H, Kashiwagi T, Takagi H. Observation of higher-harmonic helical spin-resonance modes in the chromium spinel CdCr2O4. Phys Rev Lett 2006; 97:257202. [PMID: 17280386 DOI: 10.1103/physrevlett.97.257202] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/15/2005] [Revised: 08/04/2006] [Indexed: 05/13/2023]
Abstract
High frequency ESR measurements on the chromium spinel compound CdCr2O4 have been performed. The observed ESR modes below Hc' approximately 5.7 T can be explained well by the calculated resonance modes based on a molecular field theory assuming a helical spin structure. Other than the fundamental ones, we have succeeded in observing the higher-harmonic modes for the first time. A large change of the ESR modes above Hc' indicate that a variation of the spin structure from the helical to the four-sublattice canted one takes place around Hc'.
Collapse
Affiliation(s)
- S Kimura
- KYOKUGEN, Osaka University, Machikaneyama 1-3, Toyanaka 560-8531, Japan
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Kawamura M, Izumi Y, Tsukada N, Yashiro H, Nakatsuka S, Nakano K, Kuribayashi S, Kobayashi K. Local control of lung tumors by percutaneous fluoroscopic computer tomography guided cryoablation. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Kawamura
- Gen Thoracic Sch of Medicine Keio Univ, Tokyo, Japan; Diag Radiol Sch of Medicine Keio Univ, Tokyo, Japan
| | - Y. Izumi
- Gen Thoracic Sch of Medicine Keio Univ, Tokyo, Japan; Diag Radiol Sch of Medicine Keio Univ, Tokyo, Japan
| | - N. Tsukada
- Gen Thoracic Sch of Medicine Keio Univ, Tokyo, Japan; Diag Radiol Sch of Medicine Keio Univ, Tokyo, Japan
| | - H. Yashiro
- Gen Thoracic Sch of Medicine Keio Univ, Tokyo, Japan; Diag Radiol Sch of Medicine Keio Univ, Tokyo, Japan
| | - S. Nakatsuka
- Gen Thoracic Sch of Medicine Keio Univ, Tokyo, Japan; Diag Radiol Sch of Medicine Keio Univ, Tokyo, Japan
| | - K. Nakano
- Gen Thoracic Sch of Medicine Keio Univ, Tokyo, Japan; Diag Radiol Sch of Medicine Keio Univ, Tokyo, Japan
| | - S. Kuribayashi
- Gen Thoracic Sch of Medicine Keio Univ, Tokyo, Japan; Diag Radiol Sch of Medicine Keio Univ, Tokyo, Japan
| | - K. Kobayashi
- Gen Thoracic Sch of Medicine Keio Univ, Tokyo, Japan; Diag Radiol Sch of Medicine Keio Univ, Tokyo, Japan
| |
Collapse
|
27
|
Asano S, Yoshida A, Yashiro H, Kobayashi Y, Morisato A, Ogawa H, Takeguchi N, Morii M. The cavity structure for docking the K(+)-competitive inhibitors in the gastric proton pump. J Biol Chem 2003; 279:13968-75. [PMID: 14699149 DOI: 10.1074/jbc.m308934200] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
2-Methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine-3-acetonitrile (SCH 28080) is a reversible inhibitor specific for the gastric proton pump. The inhibition pattern is competitive with K(+). Here we studied the binding sites of this inhibitor on the putative three-dimensional structure of the gastric proton pump alpha-subunit that was constructed by homology modeling based on the structure of sarcoplasmic reticulum Ca(2+) pump. Alanine and serine mutants of Tyr(801) located in the fifth transmembrane segment of the gastric proton pump alpha-subunit retained the (86)Rb transport and K(+)-dependent ATPase (K(+)-ATPase) activities. These mutants showed 60-80-times lower sensitivity to SCH 28080 than the wild type in the (86)Rb transport activity. The K(+)-ATPase activities of these mutants were not completely inhibited by SCH 28080. The sensitivity to SCH 28080 was dependent on the bulkiness of the side chain at this position. Therefore, the side chain of Tyr(801) is important for the interaction with this inhibitor. In the three-dimensional structure of the E(2) form (conformation with high affinity for K(+)) of the gastric proton pump, Tyr(801) faces a cavity surrounded by the first, fourth, fifth, sixth, and eighth transmembrane segments and fifth/sixth, seventh/eighth, and ninth/tenth loops. SCH 28080 can dock in this cavity. However, SCH 28080 cannot dock in the same location in the E(1) form (conformation with high affinity for proton) of the gastric proton pump due to the drastic rearrangement of the transmembrane helices between the E(1) and E(2) forms. These results support the idea that this cavity is the binding pocket of SCH 28080.
Collapse
Affiliation(s)
- Shinji Asano
- Life Scientific Research Center, Faculty of Pharmaceutical Sciences, Toyama Medical & Pharmaceutical University, Toyama, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Tabuchi Y, Yashiro H, Hoshina S, Asano S, Takeguchi N. Cibenzoline, an ATP-sensitive K(+) channel blocker, binds to the K(+)-binding site from the cytoplasmic side of gastric H(+),K(+)-ATPase. Br J Pharmacol 2001; 134:1655-62. [PMID: 11739241 PMCID: PMC1572902 DOI: 10.1038/sj.bjp.0704422] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
1. Cibenzoline, (+/-)-2-(2,2-diphenylcyclopropyl-2-imidazoline succinate, has been clinically used as one of the Class I type antiarrhythmic agents and also reported to block ATP-sensitive K(+) channels in excised membranes from heart and pancreatic beta cells. In the present study, we investigated if this drug inhibited gastric H(+),K(+)-ATPase activity in vitro. 2. Cibenzoline inhibited H(+),K(+)-ATPase activity of permeabilized leaky hog gastric vesicles in a concentration-dependent manner (IC(50): 201 microM), whereas no effect was shown on Na(+),K(+)-ATPase activity of dog kidney (IC(50): >1000 microM). Similarly, cibenzoline inhibited H(+),K(+)-ATPase activity of HEK-293 cells (human embryonic kidney cell line) co-transfected with rabbit gastric H(+),K(+)-ATPase alpha- and beta-subunit cDNAs (IC(50): 183 microM). 3. In leaky gastric vesicles, inhibition of H(+),K(+)-ATPase activity by cibenzoline was attenuated by the addition of K(+) (0.5 - 5 mM) in a concentration-dependent manner. The Lineweaver-Burk plot of the H(+),K(+)-ATPase activity shows that cibenzoline increases K(m) value for K(+) without affecting V(max), indicating that this drug inhibits H(+),K(+)-ATPase activity competitively with respect to K(+). 4. The inhibitory effect of H(+),K(+)-ATPase activity by cibenzoline with normal tight gastric vesicles did not significantly differ from that with permeabilized leaky gastric vesicles, indicating that this drug reacted to the ATPase from the cytoplasmic side of the membrane. 5. These findings suggest that cibenzoline is an inhibitor of gastric H(+),K(+)-ATPase with a novel inhibition mechanism, which inhibits gastric H(+),K(+)-ATPase by binding its K(+)-recognition site from the cytoplasmic side.
Collapse
Affiliation(s)
- Y Tabuchi
- Molecular Genetics Research Center, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama City, Toyama 930-0194, Japan.
| | | | | | | | | |
Collapse
|
29
|
Fajardo M, Audebert P, Renaudin P, Yashiro H, Shepherd R, Gauthier JC, Chenais-Popovics C. Study of the ion-distribution dynamics of an aluminum laser-produced plasma with picosecond resolution. Phys Rev Lett 2001; 86:1231-1234. [PMID: 11178051 DOI: 10.1103/physrevlett.86.1231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2000] [Indexed: 05/23/2023]
Abstract
The ion-distribution dynamics of an expanding aluminum plasma produced by a nanosecond laser pulse at moderate intensity (10(13) W cm(-2)) is studied by point-projection x-ray absorption spectroscopy with unprecedented, picosecond, time resolution. We show that the ionic populations measured as a function of distance to the target and at different probing times differ markedly from those predicted by widely accepted collisional radiative models coupled to hydrodynamic simulations. We discuss the effects of radiation, conduction, and expansion cooling on the spatiotemporal ionic distribution evolution.
Collapse
Affiliation(s)
- M Fajardo
- Laboratoire pour l'Utilisation des Lasers Intenses, UMR7605, CNRS-CEA-Universite Paris VI-Ecole Polytechnique, 91128 Palaiseau, France
| | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
Gastric H+,K+-ATPase consists of alpha- and beta-subunits. The catalytic alpha-subunit contains a very unique structure consisting of lysine and glycine clusters, KKK(or KKKK)AG(G/R)GGGK-(K/R)K, in the amino-terminal cytoplasmic region. This structure is well conserved in all gastric H+,K+-ATPases from different animal species, and was postulated to be the site controlling the access of cations (or proton) to its binding site. In this report, we studied the role of this unique structure by expressing several H+,K+-ATPase mutants of the alpha-subunit together with the wild-type beta-subunit in HEK-293 cells. Even after replacing all the positively-charged amino acid residues (six lysines and one arginine) in the cluster with alanine or removing all the glycine residues in the cluster, the mutants preserved the H+,K+-ATPase activity, and showed similar affinity for ATP and K+ as well as similar pH profiles as those of wild-type H+,K+-ATPase, indicating that the cluster is not indispensable for H+,K+-ATPase activity and not directly involved in determination of the affinity for cation (proton).
Collapse
Affiliation(s)
- S Asano
- Molecular Genetics Research Center, Toyama Medical and Pharmaceutical University, Toyama, 930-0194 Japan.
| | | | | | | | | |
Collapse
|
31
|
Abstract
Large-restriction-fragment (LRF) polymorphisms in Streptococcus equi (S equi subspecies equi) were studied by pulsed-field gel electrophoresis. Five or six chromosomal fragments of between 194 and 915 kb were separated by digestion with the restriction endonuclease Notl. All 20 isolates of S equi, including 12 from independent Japanese outbreaks, four from independent American outbreaks, two from a single Irish outbreak, us vaccine strain F43, and type strain NCTC 9682 were successfully typed. Seven distinctive, reproducible and stable types were identified. The 12 Japanese isolates collected between 1992 and 1998 were of LRF type II suggesting that they were derived from the same source. The remaining eight isolates were of six types. The results indicate that LRF typing should be a useful technique for investigating the source and transmission of S equi.
Collapse
Affiliation(s)
- S Takai
- Department of Animal Hygiene, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, Japan
| | | | | | | | | | | | | |
Collapse
|
32
|
Owadano Y, Okuda I, Matsumoto Y, Matsushima I, Takahashi E, Miura E, Yashiro H, Tomie T, Kuwahara K, Shinbo M. Overview of `Super-ASHURA' KrF Laser Program. Fusion Engineering and Design 1999. [DOI: 10.1016/s0920-3796(98)00350-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
33
|
Okuda I, Takahashi E, Matsushima I, Matsumoto Y, Yashiro H, Miura E, Tomie T, Owadano Y. Performance of the `Super-ASHURA' main amplifier. Fusion Engineering and Design 1999. [DOI: 10.1016/s0920-3796(98)00349-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
34
|
Higashi A, Yashiro H, Kiyota K, Inokuchi H, Hatta H, Fujita K, Watanabe Y, Kawai K. [Validation of the hospital anxiety and depression scale in a gastro-intestinal clinic]. Nihon Shokakibyo Gakkai Zasshi 1996; 93:884-92. [PMID: 8986079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
This study examined the validity of the Japanese version of the hospital anxiety and depression scale (HAD) in a gastro-intestinal outpatient clinic. One hundred and twenty-three men and 142 women consulting a gastro-intestinal outpatient clinic at a primary care hospital in Kyoto during 1995 were surveyed. Item-remainder correlation and internal consistency were examined for reliability. Concurrent validities were examined using the stait-trait anxiety inventory (STAI) and Zung's self-rating depression scale (SDS). The prevalence of psychiatric disorder in this population ranged from 27% to 39%. Cronbach's coefficients were greater than 0.8 for the anxiety subscale and more than 0.7 for the depression subscale. Spearman's correlation of the anxiety subscale scores and the STAI were r = 0.678 for men, and r = 0.717 for women. The correlation of depression subscale scores and SDS were r = 0.457 for men, and r = 0.565 for women. It is suggested that the use of the HAD to general hospital outpatients clinic would facilitate detecting emotional disorders in outpatients.
Collapse
Affiliation(s)
- A Higashi
- Department of Preventive Medicine, Kyoto Prefectural University of Medicine
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Tarasov V, Yashiro H, Maeda K, Azumi T, Shkrob I. Spin-correlated radical pairs in micellar systems: mechanism of CIDEP and the micelle size dependence. Chem Phys 1996. [DOI: 10.1016/s0301-0104(96)00145-0] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
36
|
Hill RA, Esterowitz T, Ryan J, Liaw LH, Nelson JS, Yashiro H, Krasieva T, Berns MW. Photodynamic laser cyclodestruction with chloroaluminum sulfonated phthalocyanine (CASPc) or Photofrin (PII) vs. Nd:YAG laser cyclodestruction in a pigmented rabbit model. Lasers Surg Med 1995; 17:166-71. [PMID: 8569412 DOI: 10.1002/lsm.1900170205] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
BACKGROUND AND OBJECTIVE To investigate Photofrin (PII) and CASPc for photodynamic therapy (PDT) of the ciliary body in rabbits. STUDY DESIGN/MATERIALS AND METHODS PII (10 mg/kg) or CASPc (1 mg/kg) was given by ear vein. Pharmacokinetics were studied in frozen sections by fluorescence microscopy (CCD camera based low light detection system with digital image processing) at 1 and 24 h (8 rabbits; 16 eyes). Laser light was delivered (argon pumped dye laser; 630 and 675 nm; 8 rabbits; 16 eyes) by contact fiberoptic. To compensate for iris attenuation, irradiance was 125 mW/cm2 (20, 40, 80, or 160 J/cm2). Controls (4 rabbits; 8 eyes) received laser light without photochemicals (OD) and for comparison, continuous wave Nd:YAG laser by fiberoptic (0.8-1.2J; OS). RESULTS Localization studies showed intravascular distribution with some selective ciliary body distribution at 24 h (PII > CASPc). Rabbits treated with PII or CASPc exhibited variable amounts of gross ciliary body edema, infarction, and necrosis by 24-48 h. This response was not seen in PDT control tissues; damage was seen in the iris and ciliary body, with partial vacuolization of the pigment epithelium. CONCLUSION PDT may offer a more selective approach to ciliary body destruction. A small but significant thermal effect was seen during PDT from melanin photon uptake with damage to iris and ciliary body. Thermal damage and potential interaction with ocular visual pigments may limit use of these photochemicals and wavelengths for PDT of the ciliary body.
Collapse
Affiliation(s)
- R A Hill
- Department of Ophthalmology, University of California, Irvine 92717, USA
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Yashiro H, Higashi A, Miyaji N, Ozasa K, Watanabe Y, Aoike A, Kawai K. [A comparative study of psycho-social factors in peptic ulcer disease]. Nihon Shokakibyo Gakkai Zasshi 1994; 91:1075-85. [PMID: 8028200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
To evaluate the psycho-social factors of peptic ulcer, we carried out a comparative study. Seventy-six men and 19 women with peptic ulcers diagnosed at seven hospitals in Kyoto, Osaka and Hyogo Prefectures in Japan were surveyed during November 1990 about their daily hassles, depressive state, social support and life style using a self-administered questionnaire. The results were compared to those for two control groups. One control group was diagnosed with normal, atrophic gastritis, or superficial gastritis by the gastro-duodenal endoscopic examinations in the same hospitals. The other control group consisted of participants in a health-screening examination at one of the above hospitals. There were no significant differences between patients and controls in daily hassles, depressive state, and social support. However, being unmarried, smoking and eating irregular meals significantly increased the relative risk of peptic ulcer in men and family history of peptic ulcer significantly increased the risk in women.
Collapse
Affiliation(s)
- H Yashiro
- Department of Internal Medicine, Second Okamoto General Hospital
| | | | | | | | | | | | | |
Collapse
|
38
|
Hill RA, Le MT, Yashiro H, Constan C, Treadway A, Stern D, Lesiecki ML, Brown L, Berns MW. Ab-interno erbium (Er):YAG laser sclerostomy with iridotomy in Dutch cross rabbits. Lasers Surg Med 1993; 13:559-64. [PMID: 8264328 DOI: 10.1002/lsm.1900130511] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
An ab-interno technique using a pigmented rabbit model has been developed that uses a pulsed erbium:YAG laser to create an iridotomy with a sclerostomy through the same corneal incision. Laser energy was delivered with an articulated arm terminating in side-firing (850 or 650 microns OD) or end-firing (850 or 400 microns OD) fiber optic endoprobes, which allowed iridotomies and sclerostomies, respectively, to be created. Initially, sclerostomies (8-10, 8 mJ/300 microseconds pulses) and basal iridotomies (1-3, 4 mJ/200 microseconds pulses) were created with the larger probes. Problems encountered with this technique included corneal decompensation and rapid formation of peripheral anterior synechiae with occlusion of sclerostomies. The smaller endoprobes were then used to create mid-peripheral iridotomies and sclerostomies utilizing the same energy parameters. Sclerostomies created in this manner remained patent in the first postoperative week until the animals were sacrificed to obtain material for histologic study.
Collapse
Affiliation(s)
- R A Hill
- Department of Ophthalmology, Beckman Laser Institute and Medical Clinic, University of California, Irvine 92717
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Kobayashi S, Kanakubo Y, Iwasaki Y, Yashiro H, Iizuka S, Kato H, Suzuki H, Sanada Y, Sotoma T. [A survey on the current status and trends in bladder irrigation]. Hinyokika Kiyo 1985; 31:1243-52. [PMID: 4061222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Questionnaires were sent to pharmacies and clinics in 592 Japanese hospitals from July to November, 1983 to investigate the use of bladder irrigation. The questionnaires were completed and returned by 418 hospitals, the rate of response being 70.8%. Fifty eight kinds of irrigants were prepared in hospital pharmacies and were reported to have been used in 1,171 patients. Of these irrigants, chlorhexidine gluconate accounted for 18.8%, Polymyxin B for 17.1%, normal saline for 13.3%, potassium permanganate for 6.9%, and boric acid for 5.7%. Chlorhexidine gluconate was usually used at a concentration of 0.02% (in 79% of the total use of the agent), Polymyxin B at 0.01%, 0.02% and 0.05%, potassium permanganate at 0.01% and 0.02% (in 73% of the total use), and acrinol at 0.01%, 0.05% and 0.1%. To questions about side effects, such as irritation, 65 hospitals answered that irritation had occurred. Irrigants were most frequently supplied to non-disposable 500 ml containers used exclusively for this purpose, 38% of all the hospitals using this method. Non-disposable 1 liter containers for exclusive use with bladder irrigants were used in 23% of the hospitals. Purified water was most frequently used to prepare the bladder irrigants (in 35% of hospitals) followed in descending order, by sterile purified water in 33%, and distilled water for injection in 26%. Water for irrigants was prepared at the hospital in 83% of the hospitals. The time of storage of the prepared bladder irrigants was mostly one week to one month, and was within one month in 78% of the hospitals. Seventeen percent of the hospitals answered that the preparation of bladder irrigants was a cause of overwork in their pharmacies. Irrigants against Pseudomonas infections were prepared separately in 40% of the hospitals, and there was no such regulation in 37%. Forty four agents were used to prepare such irrigants, and Polymyxin B accounted for 50%. The use of these agents significantly (P less than 0.001) differed between hospitals. Forty eight percent of the hospitals made special preparations for patients with clouded urine, and there was no such regulation in 46%. Thirty nine agents were used for this purpose. Polymyxin B was used in 30%, and chlorhexidine gluconate in 19%. The use of these agents differed significantly (P less than 0.001) between hospitals.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
|
40
|
Tanaka S, Hatakoshi G, Yashiro H, Umegaki S. Out-of-phase properties of optical-waveguide Bragg-grating lenses. Appl Opt 1984; 23:1754. [PMID: 18212898 DOI: 10.1364/ao.23.001754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
|
41
|
|
42
|
Sasaki S, Masaki N, Yashiro H, Kudo M, Kimura K, Takebe K. Degradation of insulin in perfused liver and skeletal muscle and insulin secretion in perfused pancreas of liver injury rat. Horm Metab Res 1981; 13:561-4. [PMID: 7028590 DOI: 10.1055/s-2007-1019335] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
To study the mechanism of hyperinsulinism and glucose intolerance in liver disease, insulin removal rate by liver and muscle, glucose uptake by muscle and insulin secretion from pancreas were measured using the perfusion in rats with injured liver induced by carbon tetrachloride (liver injury rat). In the perfused liver, insulin removal rate of liver injury rat decreased to 62% of that of normal rat, but it did not alter in the perfused muscle. Insulin response to arginine by the perfused pancreas of liver injury rat was similar to that of normal rat. Before insulin infusion, glucose uptake by the perfused muscle was similar in liver injury rat and normal rat. In contrast, during insulin infusion, glucose uptake by the perfused muscle was 1.5 times higher in liver injury rat than in normal rat. These results suggested that the peripheral hyperinsulinism was solely due to decreased hepatic insulin degradation, but not hypersecretion of insulin from pancreas and furthermore, might suggest that the insulin resistance was related to appearance of biologically inactive endogenous insulin, because of exogenous insulin completely acting on peripheral target tissue.
Collapse
|
43
|
Sugai S, Yashiro H, Nitta K. Equilibrium and kinetics of the unfolding of alpha-lactalbumin by guanidine hydrochloride. Biochim Biophys Acta 1973; 328:35-41. [PMID: 4761990 DOI: 10.1016/0005-2795(73)90327-9] [Citation(s) in RCA: 39] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|